Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2025 Earnings Call Transcript
Operator: Good afternoon. My name is Chloe, and I will be your conference operator for the Vaxcyte Fourth Quarter and Full Year 2025 Financial Results Conference Call.
Vaxcyte Inc. (PCVX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 10,724,599 | $494,832,998 | -11% | 5.07% |
| 2. | Paradigm Biocapital Advisors Senai Asefaw | 4,068,020 | $187,698,443 | +8% | 4.79% |
| 3. | Deep Track Capital David Kroin | 4,000,000 | $184,560,000 | +34% | 3.29% |
| 4. | D E Shaw D. E. Shaw | 3,631,053 | $167,536,785 | -16% | 0.09% |
| 5. | Kynam Capital Derrick Tang | 2,922,335 | $134,836,537 | -5% | 8.61% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 937,500 | $15,000,000.00 | 5,156,553 | 2020-06-16 | Filing | |
| $16.00 | 12,500 | $200,000.00 | 4,168,718 | 2020-06-16 | Filing | |
| $16.00 | 93,000 | $1,488,000.00 | 2,222,967 | 2020-06-16 | Filing | |
| $16.00 | 250,000 | $4,000,000.00 | 2,309,554 | 2020-06-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $56.26 | 405 | $22,786.52 | 28,975 | 2026-03-17 | Filing | |
| $55.39 | 1,487 | $82,360.47 | 29,380 | 2026-03-17 | Filing | |
| $58.59 | 2,500 | $146,481.75 | 30,867 | 2026-03-11 | Filing | |
| $59.16 | 4,968 | $293,906.88 | 166,818 | 2026-03-10 | Filing | |
| $58.32 | 2,427 | $141,532.93 | 171,786 | 2026-03-10 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 186 | $10,135 | 0.01% |
News See All
Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials
Vaxcyte Inc. (NASDAQ:PCVX) is one of the best stocks to buy and hold for the next 6 months. On February 11, Vaxcyte Inc.
Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating
Vaxcyte Inc. (NASDAQ:PCVX) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, Vaxcyte Inc.
13 Hot Stocks to Buy with the Highest Upside Potential
On average, equities are expected continue to deliver positive results in 2026, this time with greater breadth across sectors, styles, and regions, compared to the other periods of the recent bull market...
10 Best Stocks to Buy and Hold for the Next 6 Months
Investors are becoming more selective toward tech stocks amid valuation concerns, with the overall market at all-time highs.
Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX)
On January 23, Cantor Fitzgerald maintained its Overweight rating on Vaxcyte Incorporated (NASDAQ:PCVX), highlighting continued progress across the company’s clinical pipeline.
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Evercore ISI Rates Vaxcyte Inc. (PCVX) as an Overweight Following CDC Changes to Childhood Vaccination Recommendations
Vaxcyte Inc. (NASDAQ:PCVX) is one of the best US stocks to buy under $50. On January 23, Cantor Fitzgerald reaffirmed its Overweight rating on Vaxcyte Inc.
10 Best US Stocks to Buy Under $50
Volatility is on the rise amid a return to tariff-fuelled market pullbacks.
What Makes Vaxcyte (PCVX) So Attractive
On December 9, BTIG analyst Thomas Shrader reiterated his bullish view of Vaxcyte Inc. (NASDAQ:PCVX). He assigned a Buy rating to the stock with a target price of $85.
Hedge Fund Resource Center